Neurotheranostics: The Next Frontier for Health Span.

With an aging U.S. population, advancements in the treatment of Alzheimer disease (AD) and other neurodegenerative diseases are key to the maximization of health span. The recent approval of 2 antiamyloid antibodies, which decrease brain amyloid load, places us on the cusp of breakthrough therapies that target the mechanism of the disease rather than just treating the symptoms. Although the trials that led to these approvals studied patients with mild early symptoms, multiple ongoing trials have enrolled cognitively normal patients screened for AD biomarkers including risk factors for amyloid positivity, family history, and genetic markers. Thus, amyloid PET can help identify an at-risk population that can be enrolled for antiamyloid therapy to prevent AD symptoms from ever developing. In this review, we examine the paradigm of neurotheranostics and how PET biomarkers of amyloid, tau, inflammation, and neurodegeneration could characterize the pathologic stage of AD and therefore allow for personalized therapy.

[1]  R. Bateman,et al.  Lecanemab in Early Alzheimer's Disease. , 2022, The New England journal of medicine.

[2]  J. Seibyl.  Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders , 2022, The Journal of Nuclear Medicine.

[3]  A. Abbott.  Could drugs prevent Alzheimer’s? These trials aim to find out , 2022, Nature.

[4]  J. Weuve,et al.  Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060) , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[5]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[6]  M. Solas,et al.  Biomarkers in Alzheimer’s disease , 2020, Advances in laboratory medicine.

[7]  W. Wong.  Economic burden of Alzheimer disease and managed care considerations. , 2020, The American journal of managed care.

[8]  Keith A. Johnson,et al.  Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. , 2020, JAMA neurology.

[9]  Carrie D. Patnode,et al.  Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2020, JAMA.

[10]  David T. Jones,et al.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.

[11]  J. Hodges,et al.  Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders , 2019, International journal of molecular sciences.

[12]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[13]  Jennifer Weuve,et al.  Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study , 2018, Alzheimer's & Dementia.

[14]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[15]  Brian A. Gordon,et al.  Tau Kinetics in Neurons and the Human Central Nervous System , 2018, Neuron.

[16]  J. Hardy,et al.  Alzheimer's disease , 2018, European journal of neurology.

[17]  Roy W Jones,et al.  On the path to 2025: understanding the Alzheimer’s disease continuum , 2017, Alzheimer's Research & Therapy.

[18]  L. Chambers,et al.  Is Dementia Screening of Apparently Healthy Individuals Justified? , 2017, Advances in preventive medicine.

[19]  A. Jemal,et al.  The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections , 2016, CA: a cancer journal for clinicians.

[20]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[21]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[22]  Eileen M. Crimmins,et al.  Lifespan and Healthspan: Past, Present, and Promise. , 2015, The Gerontologist.

[23]  P. Wolf,et al.  Gender and incidence of dementia in the Framingham Heart Study from mid-adult life , 2015, Alzheimer's & Dementia.

[24]  C. Corot,et al.  Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. , 2013, Quantitative imaging in medicine and surgery.

[25]  Francis J McMahon,et al.  In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. , 2013, Brain : a journal of neurology.

[26]  B. Tejada-Vera.  Mortality from Alzheimer's disease in the United States: data for 2000 and 2010. , 2013, NCHS data brief.

[27]  L. Beckett,et al.  Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050 , 2001, Alzheimer disease and associated disorders.

[28]  V. Freedman,et al.  Aggregate changes in severe cognitive impairment among older Americans: 1993 and 1998. , 2001, The journals of gerontology. Series B, Psychological sciences and social sciences.

[29]  E. Crimmins,et al.  Further evidence on recent trends in the prevalence and incidence of disability among older Americans from two sources: the LSOA and the NHIS. , 1997, The journals of gerontology. Series B, Psychological sciences and social sciences.

[30]  Sukja Ko,et al.  Analysis of the Effects of Obesity Control on Life Expectancy and Healthy Life Expectancy , 2013 .

[31]  Vern R. Walker,et al.  Study results. , 2007, Nursing management.